Nebivolol, Lifestyle Modification and Arterial Stiffness
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Numerous anti-hypertensive drugs have been reported to be efficacious in reducing central
arterial stiffness and these effects may contribute to improved outcomes in hypertensive
patients. However, the results of several studies suggest that beta-blockers may actually
increase arterial stiffness. In contrast, there is limited evidence to suggest that
nebivolol, a third generation beta-blocker that augments release of vascular nitric oxide,
reduces central arterial stiffness in hypertensive individuals. Unfortunately, only a few
studies have addressed this issue and all of these studies relied on indirect, blood pressure
dependent measures of arterial stiffness. In addition, none of these studies focused on
middle-aged and older, obese hypertensives, a population with accelerated arterial stiffening
and at risk for cardiovascular diseases. Thus, the potential utility of nebivolol as a
therapy to reduce large artery stiffness, particularly among the latter population, remains
unclear.
Phase:
Phase 4
Details
Lead Sponsor:
Virginia Polytechnic Institute and State University